MGMT and central nervous system cancer: In recent years, wild-type isocitrate dehydrogenase 1 (IDH1) mutation, 1p/19q codeletion, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation have been widely applied for molecular classification of glioma, but these markers are of limited value for predicting prognosis and response to therapy.